Earnings call transcript: Schrödinger misses EPS but beats revenue in Q1 2026

Schrödinger Q1 2026 revenue came in at $58.6 million, beating expectations by 21.78%, but EPS missed at -$0.81 versus -$0.64 expected. Drug discovery revenue jumped 124% year over year to $22.9 million, while software gross margin fell to 69% from 80% as the company accelerates its move to hosted licensing. Management reaffirmed full-year 2026 guidance and highlighted Bunsen, its agentic AI co-scientist, as a potential growth driver, though aftermarket shares slipped 0.31%.

Analysis

SDGR’s print is less about the headline beat than the shape of the business mix. The key second-order read-through is that hosted migration is intentionally suppressing near-term recognition while increasing customer lock-in and future visibility; that creates a temporary valuation trap because reported revenue and gross margin will look worse exactly as the commercial engine strengthens. The market is likely underestimating how much ACV growth plus early conversion of legacy on-prem contracts can offset the accounting drag over the next 2-3 quarters.

The bigger strategic signal is that the company is monetizing two different option sets: software usage expansion through agentic tooling, and balance-sheet optionality from its therapeutics/venture portfolio. If Bunsen actually lowers workflow friction for expert users, the first bottleneck becomes not demand creation but capacity monetization — which is favorable for a throughput-based model and could accelerate ARPU before broad enterprise adoption even arrives. On the therapeutics side, the Ajax transaction reinforces that co-developed assets are becoming a meaningful financing engine for the platform, which should compress the market’s perceived “cash burn” duration.

The main risk is that investors continue to anchor on GAAP losses and miss that the transition period could last another two quarters, especially with Q4 still the largest renewal cluster. A softer biotech funding tape would hurt new customer additions and could expose how much of the current momentum is renewal-driven rather than net-new demand. The contrarian view is that the stock may be over-discounting the hosted transition and underpricing the probability that ACV, equity gains, and improved software utilization create a re-rating before profitability is visible on reported EPS.

Key Decisions for Investors

• Go long SDGR over a 3-6 month horizon on weakness below the post-earnings range; thesis is that ACV and hosted conversion re-rate the name before GAAP margins recover. Target 20-30% upside if Q2 confirms mid-teens ACV growth.
• Buy SDGR Jan-2027 call spreads to express the view that profitability timing is less important than commercial compounding. Structure for limited premium outlay with upside tied to hosted migration and Bunsen monetization.
• Pair trade: long SDGR / short a profitable software comp proxy in the life-sciences stack for 1-2 quarters, betting that SDGR’s multiple expands as recognition lag narrows. Risk: if biotech funding weakens, the long leg underperforms.
• Sell near-dated SDGR puts only if implied vol spikes on margin noise; the near-term downside is more about narrative than fundamentals, and the balance sheet plus cash from Ajax reduce tail risk. Avoid if Q2 renewal commentary weakens.
• For fundamental accounts, add a catalyst alert on the next hosted revenue disclosure and Bunsen commercialization details; that is the inflection point where the market will start modeling higher throughput per customer rather than just contract count.